Search

Your search keyword '"Cevimeline"' showing total 26 results
Start Over Descriptor "Cevimeline" Publication Type News
26 results on '"Cevimeline"'

1. Sjogren's syndrome

Subjects
Rheumatoid factor, Cevimeline, Arthritis -- Diagnosis, Health
Abstract

Overview Sjogren's (SHOW-grins) syndrome is a disorder of your immune system identified by its two most common symptoms -- dry eyes and a dry mouth. The condition often accompanies other [...]

Published
2024

2. Research from Fujian Medical University in Antipsychotics Provides New Insights (Olanzapine Modulate Lipid Metabolism and Adipose Tissue Accumulation via Hepatic Muscarinic M3 Receptor-Mediated Alk-Related Signaling)

Subjects
Medical research, Medicine, Experimental, Adipose tissues, Olanzapine, Cevimeline, Medical colleges
Abstract

2024 JUL 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in antipsychotics. According to news reporting out of Fuzhou, [...]

Published
2024

3. Patent Application Titled 'Composition Comprising Beta Blocker And Cholinesterase Inhibitor For Treatment Of Neurodegenerative Disease' Published Online (USPTO 20240148711)

Subjects
Nervous system diseases, Cevimeline, Anti-arrhythmia drugs -- Intellectual property, Antihypertensive drugs, Adrenergic beta blockers, Business, Health
Abstract

2024 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Patent Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent [...]

Published
2024

5. Reports from National Academy of Sciences of Ukraine Advance Knowledge in Biochemistry (A new affine inhibitor of sodium pump thiacalix[4]arene S-1193 increases the intracellular concentration of Ca ions and modifies myometrium contractility)

Subjects
Biochemistry, Adenosine triphosphatase, Cevimeline, Biological sciences, Health, National Academy of Sciences
Abstract

2024 JAN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Fresh data on biochemistry are presented in a new report. According to news reporting [...]

Published
2024

6. Patent Issued for Muscarinic M1 receptor agonists (USPTO 11793817)

Subjects
Cevimeline, Health, Psychology and mental health
Abstract

2023 NOV 13 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Heptares Therapeutics Limited (Cambridge, United Kingdom) has been issued patent number 11793817, according [...]

Published
2023

7. MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Subjects
Xerostomia -- Care and treatment, Cevimeline, Radiation, Clinical trials, Banking, finance and accounting industries, Business
Abstract

Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 months Increases in whole saliva flow rates observed [...]

Published
2023

9. MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Subjects
Xerostomia -- Care and treatment, Cevimeline, Radiation, Clinical trials, Banking, finance and accounting industries, Business
Abstract

Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohorts Increases in whole saliva flow rates were seen [...]

Published
2022

10. Japan,United States : Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Subjects
Daiichi Sankyo Company Ltd. -- Mergers, acquisitions and divestments, Cevimeline, Company acquisition/merger, Business, international, Benicar (Medication), Welchol (Medication)
Abstract

Agreement is part of Daiichi Sankyos five-year mid-term strategy to transform to a structure primarily focused on patented drugs Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) [...]

Published
2022

11. In the United States, Daiichi Sankyo will sell certain legacy cardiovascular and other products to Cosette Pharmaceuticals, focusing on its oncology portfolio

Subjects
Daiichi Sankyo Company Ltd., Cevimeline, Pharmaceutical industry, General interest, News, opinion and commentary, Benicar (Medication), Welchol (Medication)
Abstract

TOKYO & BASKING RIDGE, N.J.: Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) have entered into an agreement with Cosette Pharmaceuticals, Inc. whereby Daiichi Sankyo divested and [...]

Published
2022

12. Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Subjects
Daiichi Sankyo Company Ltd. -- Mergers, acquisitions and divestments, Cevimeline, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, General interest, News, opinion and commentary, Benicar (Medication), Tribenzor (Medication), Welchol (Medication), Effient (Medication), Evoxac (Medication)
Abstract

TOKYO & BASKING RIDGE, N.J.: Daiichi Sankyo has issued the following news release: Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) have entered into an agreement with [...]

Published
2022

13. Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo

Subjects
Daiichi Sankyo Company Ltd., Cevimeline, Pharmaceutical industry, General interest, News, opinion and commentary, Benicar (Medication), Tribenzor (Medication), Welchol (Medication), Effient (Medication), Evoxac (Medication)
Abstract

BRIDGEWATER, N.J.: Cosette Pharmaceuticals, Inc. has issued the following news release: Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that it has closed a transaction to acquire [...]

Published
2022

14. Daiichi Sankyo to divest certain cardiovascular and other legacy products to Cosette Pharmaceuticals in the US, shifting focus to oncology portfolio

Subjects
Daiichi Sankyo Company Ltd. -- Mergers, acquisitions and divestments, Cevimeline, Pharmaceutical industry -- Mergers, acquisitions and divestments, Hydrochlorothiazide, Company acquisition/merger, Business, Chemicals, plastics and rubber industries, Benicar (Medication), Tribenzor (Medication), Welchol (Medication)
Abstract

Daiichi Sankyo Company Limited and Daiichi Sankyo Inc (hereafter, Daiichi Sankyo) have entered into an agreement with Cosette Pharmaceuticals Inc whereby Daiichi Sankyo divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the US: AZOR (amlodipine/olmesartan medoxomil); BENICAR (olmesartan medoxomil); BENICAR HCT (olmesartan medoxomil/hydrochlorothiazide); EFFIENT (prasugrel); EVOXAC (cevimeline HCL); TRIBENZOR (olmesartan medoxomil/amlodipine/hydrochlorothiazide); WELCHOL (colesevelam HCL) tablets; WELCHOL (colesevelam HCL) Oral Suspension. No other products are impacted by this agreement and no roles will be eliminated at Daiichi Sankyo related to this agreement. The agreement outlines a 30-month transition period during which Daiichi Sankyo and Cosette Pharmaceuticals will transfer responsibilities for the manufacture, supply and commercialization of these products, including quality assurance, pharmacovigilance and regulatory matters. Original source: Daiichi Sankyo Co Ltd, website: http://www.daiichisankyo.com/, Copyright Daiichi Sankyo Company Limited 2022., mergers and acquisitions; patents and technical know-how; amlodipine; AZOR; BENICAR HCT; cevimeline; cevimeline hydrochloride; colesevelam hydrochloride; colesevelam hydrochloride; hydrochlorothiazide; olmesartan medoxomil; olmesartan medoxomil; prasugrel; prasugrel; TRIBENZOR; Cosette Pharmaceuticals; Daiichi [...]

Published
2022

15. MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Subjects
Xerostomia, Cevimeline, Radiation, Clinical trials, Banking, finance and accounting industries, Business
Abstract

LONDON and NEW YORK, Dec 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Clinically meaningful improvements in xerostomia symptoms and disease burden reported in two validated Patient Reported Outcome (PRO) [...]

Published
2021

19. Researchers Submit Patent Application, 'Detection Of Autoreactive Fecal Immunoglobulin A (Iga) For Diagnosis Of Lupus', for Approval (USPTO 20210349094)

Subjects
Basiliximab -- Intellectual property, Ipilimumab, Lupus -- Development and progression, Autoimmunity, Antiarthritic agents -- Intellectual property, Systemic lupus erythematosus -- Development and progression, Cevimeline, Immunoglobulin A, Monoclonal antibodies, Health
Abstract

2021 DEC 1 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor Vasu, Chenthamarakshan [...]

Published
2021

20. Researchers Submit Patent Application, 'Treatment Of Skin Disorders With Compositions Comprising An Egfr Inhibitor', for Approval (USPTO 20210346380)

Subjects
Tetracycline -- Intellectual property, Antineoplastic agents -- Intellectual property, Tofacitinib, Dermatology -- Formulae, receipts, prescriptions, Cevimeline, Skin, Dermatologic agents -- Intellectual property, Pimecrolimus, Tetracyclines -- Intellectual property, Epidermal growth factor, Roflumilast -- Intellectual property, Antimitotic agents -- Intellectual property, Business, Health, Health care industry
Abstract

2021 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors ARKIN, Moshe [...]

Published
2021

21. Challenges in Identifying Sjogren's Syndrome

Author

Brody, Jane E.

Subjects
Sjogren's syndrome -- Diagnosis -- Care and treatment, Physicians, Cevimeline, Dehydration (Physiology), Xerostomia, Teachers, General interest, News, opinion and commentary
Abstract

Angelica Divinagracia, a 54-year-old fitness instructor in Los Angeles, woke one morning with her tongue literally stuck to the roof of her mouth. Though she normally drank lots of water, [...]

Published
2019

23. Sjogren's Syndrome (SS) Market Insights, Epidemiology and Market Forecast, 2028

Subjects
Gilead Sciences Inc. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Biological products industry -- Forecasts and trends, Cevimeline, Brand equity, Epidemiology, Belimumab, Evidence-based medicine, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, News, opinion and commentary
Abstract

DUBLIN, Oct. 21, 2019 /PRNewswire/ -- The 'Sjogren's Syndrome (SS) - Market Insights, Epidemiology and Market Forecast to 2028' drug pipelines has been added toResearchAndMarkets.com's offering. The report provides the [...]

Published
2019

26. 'Diagnostic For Sjorgen'S Syndrome Based On A Biomarker' in Patent Application Approval Process (USPTO 20190086425)

Subjects
Amino acids -- Intellectual property, Loteprednol -- Intellectual property, Cevimeline, Editors, Biotechnology, Biotechnology industry, Biological sciences, Business
Abstract

2019 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- A patent application by the inventors White, Earl Lee (Iola, TX); Dawson, Kevin (Pasadena, [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results